Silence Therapeutics (SLN) Stock News
$SLN · NASDAQ · 2 stories in 30 daysBORSA has published 2 stories on Silence Therapeutics (SLN) in the past 30 days, 1 of them high impact. BORSA’s news read on SLN is bullish at 72/100, based on 2 company events over the past 7 days. Silence Therapeutics’ next earnings report is scheduled for Thursday, Nov 5.
The wire on $SLN
newest first · updated · direct subject stories onlyGermany's Merck to buy Silence Therapeutics for $20 per ADS in cash
Germany's Merck to buy Silence Therapeutics for $20 per ADS in cash.
neutral 50 · impact 30Silence Therapeutics to be acquired for $20/ADS in all-cash deal valued at $1.3B
Silence Therapeutics PLC ADR (SLN) halted then announced an all-cash acquisition at $20 per ADS, a 130% premium to the Oct 16 close, valuing the company at about $1.3 billion.
bullish 90 · impact 80The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
BORSAPLUSNews on Price · Earnings read · Flow and ownership · Options context
Create a free account · no card